<2>Sweden Rejects Subsidy for Weight Loss Drug Semaglutide due to Economic Concerns
<3>Background on Semaglutide and Weight Loss
The glucagon-like peptide-1 receptor agonist semaglutide, sold under the brand name Wegovy, has been a topic of interest in the medical community for its potential in aiding weight loss. Manufactured by Novo Nordisk, semaglutide has been shown to be effective in reducing body weight in clinical trials. However, the Swedish drug watchdog, the Dental and Pharmaceutical Benefits Agency (TLV), has recently rejected an application for a limited subsidy to cover the costs of the drug for certain patients.
<3>TLV’s Decision and Concerns
The TLV cited a “high risk that the drug will be used for more patients than intended, so called ‘subsidy slippage,'” as the reason for rejecting the application. This concern is rooted in the fear that if the drug is subsidized, it may be prescribed to patients outside of the limited criteria being considered, which could have “major economic consequences.” The TLV’s decision means that patients will have to pay for the drug out of pocket.
<3>Implications of the Decision
The rejection of